Protein versus DNA as a marker for peripheral blood mononuclear cell counting

por Jansen, Robert S., Rosing, Hilde, Schellens, Jan H. M., Beijnen, Jos H.
Publicado 2009

Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers

por van den Broek, Irene, Sparidans, Rolf W., Schellens, Jan H. M., Beijnen, Jos H.
Publicado 2010

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs

por Kip, Anke E., Schellens, Jan H. M., Beijnen, Jos H., Dorlo, Thomas P. C.
Publicado 2017

Treatment Individualization in Colorectal Cancer

por van Geel, Robin M. J. M., Beijnen, Jos H., Bernards, René, Schellens, Jan H.M.
Publicado 2015

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

por Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
Publicado 2011

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

por Verheijen, Remy B., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R., Steeghs, Neeltje
Publicado 2017

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar()

por Sawicki, Emilia, Hillebrand, Michel J., Rosing, Hilde, Schellens, Jan H.M., Nuijen, Bastiaan, Beijnen, Jos H.
Publicado 2016

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents

por Zandvliet, Anthe S., Karlsson, Mats O., Schellens, Jan H. M., Copalu, William, Beijnen, Jos H., Huitema, Alwin D. R.
Publicado 2009

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

por Verheijen, Remy B., Yu, Huixin, Schellens, Jan H.M., Beijnen, Jos H., Steeghs, Neeltje, Huitema, Alwin D.R.
Publicado 2017

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer

por Crombag, Marie-Rose B.S., Joerger, Markus, Thürlimann, Beat, Schellens, Jan H.M., Beijnen, Jos H., Huitema, Alwin D.R.
Publicado 2016

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses

por Keizer, Ron J, Jansen, Robert S, Rosing, Hilde, Thijssen, Bas, Beijnen, Jos H, Schellens, Jan H M, Huitema, Alwin D R
Publicado 2015

Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy

por van Hasselt, J. G. Coen, Allegaert, Karel, van Calsteren, Kristel, Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
Publicado 2014

Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy”

por van Hasselt, J. G. Coen, Allegaert, Karel, van Calsteren, Kristel, Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
Publicado 2015

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative a...

por Schouten, Philip C., Dackus, Gwen M. H. E., Marchetti, Serena, van Tinteren, Harm, Sonke, Gabe S., Schellens, Jan H. M., Linn, Sabine C.
Publicado 2016

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial

por Verheijen, Remy B., Atrafi, Florence, Schellens, Jan H. M., Beijnen, Jos H., Huitema, Alwin D. R., Mathijssen, Ron H. J., Steeghs, Neeltje
Publicado 2017

Pharmacokinetics and Excretion of (14)C-Bendamustine in Patients with Relapsed or Refractory Malignancy

por Dubbelman, Anne-Charlotte, Rosing, Hilde, Darwish, Mona, D’Andrea, Denise, Bond, Mary, Hellriegel, Edward, Robertson, Philmore, Beijnen, Jos H., Schellens, Jan H. M.
Publicado 2013

Fixed Dosing of Monoclonal Antibodies in Oncology

por Hendrikx, Jeroen J.M.A., Haanen, John B.A.G., Voest, Emile E., Schellens, Jan H.M., Huitema, Alwin D.R., Beijnen, Jos H.
Publicado 2017

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

por Deenen, Maarten J., Klümpen, Heinz-Josef, Richel, Dick J., Sparidans, Rolf W., Weterman, Mariette J., Beijnen, Jos H., Schellens, Jan H. M., Wilmink, Johanna W.
Publicado 2011

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis

por Kip, Anke E., Wasunna, Monique, Alves, Fabiana, Schellens, Jan H. M., Beijnen, Jos H., Musa, Ahmed M., Khalil, Eltahir A. G., Dorlo, Thomas P. C.
Publicado 2018

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in...

por Leijen, Suzanne, Soetekouw, Patricia M. M. B., Jeffry Evans, T. R., Nicolson, Marianne, Schellens, Jan H. M., Learoyd, Maria, Grinsted, Lynda, Zazulina, Victoria, Pwint, Thinn, Middleton, Mark
Publicado 2011